Showing results (331-340 of 398) with videos related to
Sort By:
Pageof 40
European Journal of Heart Failure|October 30, 2018
Association with outcomes and response to treatment of trimethylamine N-oxide in heart failure: results from BIOSTAT-CHFToru Suzuki, Yoshiyuki Yazaki, Adriaan A Voors, et al.Journal of the American College of Cardiology|February 2, 2018
Biomarker-Guided Versus Guideline-Based Treatment of Patients With Heart Failure: Results From BIOSTAT-CHFWouter Ouwerkerk, Aeilko H Zwinderman, Leong L Ng, et al.International Journal of Cardiology|November 29, 2018
Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fractionKoen W Streng, Jan F Nauta, Hans L Hillege, et al.American Heart Journal|May 13, 2015
Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placeboRhonda Bentley-Lewis, David Aguilar, Matthew C Riddle, et al.Cardiovascular Research|October 1, 2020
Differences in biomarkers and molecular pathways according to age for patients with HFrEFJoão Pedro Ferreira, Wouter Ouwerkerk, Bernadet T Santema, et al.JACC. Heart Failure|December 1, 2022
Functional and Symptomatic Clinical Trial Endpoints: The HFC-ARC Scientific Expert PanelMitchell A Psotka, William T Abraham, Mona Fiuzat, et al.Clinical Lung Cancer|November 5, 2025
Efficacy of Neratinib-Based Therapy in ERBB2-Mutant Lung Adenocarcinomas: Findings From 2 International Phase 2 StudiesBob T Li, Leena Gandhi, Vignesh Ravichandran, et al.Journal of the American College of Cardiology|September 1, 2018
Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection FractionJasper Tromp, B Daan Westenbrink, Wouter Ouwerkerk, et al.JACC. Heart Failure|February 10, 2020
Distinct Pathological Pathways in Patients With Heart Failure and DiabetesJasper Tromp, Adriaan A Voors, Abhinav Sharma, et al.Plos Clinical Trials|November 25, 2006
Safety and reactogenicity of an MSP-1 malaria vaccine candidate: a randomized phase Ib dose-escalation trial in Kenyan childrenMark R Withers, Denise McKinney, Bernhards R Ogutu, et al.Pageof 40